Biotech ETFs Surge as the FDA Eases Its Stance

European-listed biotechnology and genomics ETFs outpaced the wider healthcare sector last week, with the six BioTech & Genomics funds tracked by Trackinsight rising 10.968% on the week against a 7.373% gain for the 29-fund Health Care sector. The move followed a signal from the US Food and Drug Administration on 17 June that it would take a more flexible approach to approving treatments for serious diseases, a shift that sent UniQure shares up by roughly 78% after the agency indicated the company could refile its Huntington's disease gene therapy using three-year clinical trial data.

A Regulatory Pivot and an M&A Wave

The week's catalyst was a clear softening in the FDA's posture. The agency suggested it would weigh accelerated approvals more readily for serious conditions, a reversal from its earlier insistence that Phase 1 and Phase 2 data alone would not suffice in UniQure's case. The change of tone has coincided with the departures of former Center for Biologics Evaluation and Research director Vinay Prasad and FDA commissioner Marty Makary. UniQure was not the only name to benefit. Over the prior two months the FDA had also opened fresh approval pathways for Atara Biotherapeutics and Replimune after earlier rejecting their cancer treatments, while Moderna received relatively favourable briefing documents ahead of an advisory committee meeting on its flu vaccine. The same backdrop could yet help Biohaven, whose neurological drug was turned down last year on insufficient clinical data.

Running alongside the regulatory thaw is a consolidation wave on track for its strongest year since the 2019 peak. Biopharma dealmaking reached roughly $106bn across 201 transactions in the first half of 2026, according to PitchBook data, and if the pace holds the full-year tally could clear $250bn, up from $209bn in 2025 and $114.8bn in a softer 2024. The average deal size has jumped to about $527.3m this year from $365m in 2025. Recent activity includes Merck's acquisition of Terns Pharmaceuticals, Novartis' purchase of Avidity Biosciences, Eli Lilly's acquisitions of Ajax Therapeutics and Kelonia Therapeutics, and Gilead Sciences' oncology-focused purchases of Arcellx and Tubulis.

The character of the wave matters as much as its size. Capital is concentrated in strategic add-ons rather than leveraged buyouts, and the favoured format is the bolt-on in the $1bn to $5bn range, typified by GSK's $2.2bn purchase of RAPT Therapeutics. Industry voices, frame these smaller deals as easier to integrate and less exposed to anti-competitive scrutiny than the $10bn to $20bn mega-mergers that have historically struggled. The activity spans oncology, metabolic disease, and central nervous system work, such as Alzheimer's, and increasingly reaches into China: buyers are acquiring ex-China rights and spinning up new companies, often domiciled in Europe or the US, to carry those assets through EMA and FDA review. The driver underneath all of it is the patent cliff, the looming loss of exclusivity on best-selling drugs that pharma must replace, a need pressing enough to sustain dealmaking even as the interest-rate backdrop has turned less supportive amid recent inflationary pressures and geopolitical conflict.

The Rally in Context

The weekly pop sits on top of a wide year-to-date gap. The BioTech & Genomics theme is up 30.115% so far in 2026, against 6.071% for the broad Health Care sector. The flow picture is less uniform than the returns. The biotech theme has drawn net inflows of roughly $30.7m year to date, but the broad Health Care sector has shed about $447.9m over the same period, even as prices rose, a sign of profit-taking and rotation rather than fresh conviction across the wider sector. The single best weekly inflow this week landed in a broad healthcare fund, not in biotech, underlining that the sector is being bought selectively rather than wholesale. The wider backdrop is more constructive than the flows suggest: public-market sentiment has improved over the past twelve months, and the biotech IPO window has effectively reopened, a thaw that has helped pull more generalist investors back towards the sector.

European Healthcare and Biotech ETF Performance

At the aggregate level, the 29 Health Care sector funds hold approximately $15.45bn in combined assets, returned 7.373% on the week and 6.071% year to date, and saw net weekly inflows of about $85.4m against year-to-date outflows of roughly $447.9m. The six BioTech & Genomics theme funds hold approximately $148.2m, returned 10.968% on the week and 30.115% year to date, with net inflows of about $8.8m on the week and $30.7m year to date.

Biotech did the heavy lifting. The iShares Nasdaq US Biotechnology UCITS ETF (BTEC) rose 8.313% on the week and leads the cut on a year-to-date basis at 17.282%, with managed assets near $863.4m. It also attracted the strongest biotech demand, taking in roughly $16.9m on the week and $23.4m year to date.

The second biotech vehicle lagged on flows. The Invesco NASDAQ Biotech UCITS ETF (SBIO) added 6.070% on the week and is up 14.859% year to date, yet despite that positive return it has seen net redemptions of about $19.8m over 2026, with only a modest $2.2m arriving this week.

US exposure set the pace among the broad healthcare names. The Xtrackers MSCI USA Health Care UCITS ETF 1D (XUHC) posted the highest weekly return in the cut at 8.742%, though it still recorded a small weekly outflow of about $2.2m and is down roughly $56.9m on the year in flow terms. The iShares S&P 500 Health Care Sector UCITS ETF (IUHC) gained 8.614% on the week and drew the largest single weekly inflow in the cut, around $30.8m, trimming its year-to-date redemptions to roughly $12.2m.

The largest fund carried the week without fresh money. The Xtrackers MSCI World Health Care UCITS ETF 1C (XDWH), at about $3.14bn the biggest vehicle in the cut, returned 7.688% on the week on zero net weekly flow, and remains down roughly $153.95m year to date.

Europe-focused names trailed, and the contrary flows sit here. The iShares MSCI Europe Health Care Sector UCITS ETF Acc (ESIH) rose 5.903% and saw buyers return this week with about $14.0m of inflows, but it still carries the cut's heaviest year-to-date redemptions at roughly $613.2m. The Amundi STOXX Europe 600 Healthcare UCITS ETF Acc (LHTC) was below at 5.762% on the week, shed about $1.6m on the week and is down roughly $150.5m on the year.

Group Data

Fund Data

Please note this article is for information purposes only and does not in any way constitute investment advice. It is essential that you seek advice from a registered financial professional prior to making any investment decision.